Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Type

Type

Guidance programme

Showing 1 to 2 of 2

TitleType
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486Technology appraisal guidance
Targeted-release budesonide for treating primary IgA nephropathy with a urine protein-to-creatinine ratio of 0.8 g/g or more (review of TA937) [ID6485]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All